{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T21:26:18Z","timestamp":1774992378647,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Nanjing Second Hospital Talent Promotion Project","award":["RCMS232013"],"award-info":[{"award-number":["RCMS232013"]}]},{"name":"Geriatric Health Research Project of Jiangsu Provincial Health Commission","award":["LKM2022037"],"award-info":[{"award-number":["LKM2022037"]}]},{"name":"Key Project of Research Project of Jiangsu Provincial Health Commission","award":["K2023018"],"award-info":[{"award-number":["K2023018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01619-w","type":"journal-article","created":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T05:45:56Z","timestamp":1743659156000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["YY1-induced transcription of AKR1C3 activates the Hedgehog signalling pathway to enhance lenalidomide resistance and glycolytic activity in multiple myeloma cells"],"prefix":"10.1007","volume":"25","author":[{"given":"Yang","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aijia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daoda","family":"Qi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengyi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zihao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"issue":"3","key":"1619_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1619_CR2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.soncn.2017.05.012","volume":"33","author":"K Brigle","year":"2017","unstructured":"Brigle K, Rogers B. Pathobiology and diagnosis of multiple myeloma. Semin Oncol Nurs. 2017;33(3):225\u201336.","journal-title":"Semin Oncol Nurs"},{"issue":"4","key":"1619_CR3","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3816\/CLM.2009.n.056","volume":"9","author":"RA Kyle","year":"2009","unstructured":"Kyle RA, Rajkumar SV. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma. 2009;9(4):278\u201388.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"2","key":"1619_CR4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/path.4712","volume":"239","author":"J Wang","year":"2016","unstructured":"Wang J, De Veirman K, Faict S, Frassanito MA, Ribatti D, Vacca A, Menu E. Multiple myeloma exosomes establish a favourable bone marrow microenvironment with enhanced angiogenesis and immunosuppression. J Pathol. 2016;239(2):162\u201373.","journal-title":"J Pathol"},{"issue":"1","key":"1619_CR5","first-page":"76","volume":"1","author":"R Ria","year":"2011","unstructured":"Ria R, Reale A, De Luisi A, Ferrucci A, Moschetta M, Vacca A. Bone marrow angiogenesis and progression in multiple myeloma. Am J Blood Res. 2011;1(1):76\u201389.","journal-title":"Am J Blood Res"},{"issue":"2","key":"1619_CR6","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.leu.2404067","volume":"20","author":"A Vacca","year":"2006","unstructured":"Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia. 2006;20(2):193\u20139.","journal-title":"Leukemia"},{"issue":"13","key":"1619_CR7","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1182\/blood-2005-07-2817","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar SV, Hayman SR, Lacy MQ, Dispenzieri A, Geyer SM, Kabat B, Zeldenrust SR, Kumar S, Greipp PR, Fonseca R, et al. Combination therapy with lenalidomide plus dexamethasone (Rev\/Dex) for newly diagnosed myeloma. Blood. 2005;106(13):4050\u20133.","journal-title":"Blood"},{"key":"1619_CR8","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"3","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F, Anderson KC. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"1619_CR9","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1158\/1078-0432.CCR-11-1221","volume":"18","author":"K Noonan","year":"2012","unstructured":"Noonan K, Rudraraju L, Ferguson A, Emerling A, Pasetti MF, Huff CA, Borrello I. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumour responses. Clin Cancer Res. 2012;18(5):1426\u201334.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1619_CR10","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","volume":"163","author":"LG Corral","year":"1999","unstructured":"Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol. 1999;163(1):380\u20136.","journal-title":"J Immunol"},{"issue":"1","key":"1619_CR11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1182\/blood.V98.1.210","volume":"98","author":"FE Davies","year":"2001","unstructured":"Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001;98(1):210\u20136.","journal-title":"Blood"},{"issue":"2","key":"1619_CR12","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2005-10-4184","volume":"108","author":"DH Chang","year":"2006","unstructured":"Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, Jagannath S, Dhodapkar MV. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood. 2006;108(2):618\u201321.","journal-title":"Blood"},{"issue":"3","key":"1619_CR13","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1124\/jpet.102.048496","volume":"305","author":"PH Schafer","year":"2003","unstructured":"Schafer PH, Gandhi AK, Loveland MA, Chen RS, Man HW, Schnetkamp PP, Wolbring G, Govinda S, Corral LG, Payvandi F, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther. 2003;305(3):1222\u201332.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1619_CR14","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/s41467-022-28515-1","volume":"13","author":"YLD Ng","year":"2022","unstructured":"Ng YLD, Ramberger E, Bohl SR, Dolnik A, Steinebach C, Conrad T, Muller S, Popp O, Kull M, Haji M, et al. Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. Nat Commun. 2022;13(1):1009.","journal-title":"Nat Commun"},{"issue":"3","key":"1619_CR15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/s41591-021-01232-w","volume":"27","author":"YC Cohen","year":"2021","unstructured":"Cohen YC, Zada M, Wang SY, Bornstein C, David E, Moshe A, Li B, Shlomi-Loubaton S, Gatt ME, Gur C, et al. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med. 2021;27(3):491\u2013503.","journal-title":"Nat Med"},{"issue":"3","key":"1619_CR16","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3390\/cancers15030963","volume":"15","author":"P Kulig","year":"2023","unstructured":"Kulig P, Milczarek S, Bakinowska E, Szalewska L, Baumert B, Machalinski B. Lenalidomide in multiple myeloma: review of resistance mechanisms, current treatment strategies and future perspectives. Cancers (Basel). 2023;15(3):963.","journal-title":"Cancers (Basel)"},{"key":"1619_CR17","doi-asserted-by":"crossref","first-page":"1378292","DOI":"10.3389\/fphar.2024.1378292","volume":"15","author":"M Li","year":"2024","unstructured":"Li M, Zhang L, Yu J, Wang X, Cheng L, Ma Z, Chen X, Wang L, Goh BC. AKR1C3 in carcinomas: from multifaceted roles to therapeutic strategies. Front Pharmacol. 2024;15:1378292.","journal-title":"Front Pharmacol"},{"issue":"5","key":"1619_CR18","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1530\/REP-11-0093","volume":"142","author":"P Naidansuren","year":"2011","unstructured":"Naidansuren P, Park CW, Kim SH, Nanjidsuren T, Park JJ, Yun SJ, Sim BW, Hwang S, Kang MH, Ryu BY, et al. Molecular characterization of bovine placental and ovarian 20alpha-hydroxysteroid dehydrogenase. Reproduction. 2011;142(5):723\u201331.","journal-title":"Reproduction"},{"issue":"18","key":"1619_CR19","doi-asserted-by":"crossref","first-page":"7681","DOI":"10.7150\/thno.74974","volume":"12","author":"C Wu","year":"2022","unstructured":"Wu C, Dai C, Li X, Sun M, Chu H, Xuan Q, Yin Y, Fang C, Yang F, Jiang Z, et al. AKR1C3-dependent lipid droplet formation confers hepatocellular carcinoma cell adaptability to targeted therapy. Theranostics. 2022;12(18):7681\u201398.","journal-title":"Theranostics"},{"issue":"6","key":"1619_CR20","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.3390\/pharmaceutics14061303","volume":"14","author":"C Navarro","year":"2022","unstructured":"Navarro C, Ortega A, Santeliz R, Garrido B, Chacin M, Galban N, Vera I, De Sanctis JB, Bermudez V. Metabolic reprogramming in cancer cells: emerging molecular mechanisms and novel therapeutic approaches. Pharmaceutics. 2022;14(6):1303.","journal-title":"Pharmaceutics"},{"issue":"3","key":"1619_CR21","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","volume":"41","author":"MV Liberti","year":"2016","unstructured":"Liberti MV, Locasale JW. The Warburg effect: how does it benefit cancer cells? Trends Biochem Sci. 2016;41(3):211\u20138.","journal-title":"Trends Biochem Sci"},{"issue":"2","key":"1619_CR22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.2174\/1871520616666161031143301","volume":"17","author":"L Schwartz","year":"2017","unstructured":"Schwartz L, Supuran CT, Alfarouk KO. The Warburg effect and the hallmarks of cancer. Anticancer Agents Med Chem. 2017;17(2):164\u201370.","journal-title":"Anticancer Agents Med Chem"},{"issue":"12","key":"1619_CR23","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/bjc.2016.152","volume":"114","author":"P Sancho","year":"2016","unstructured":"Sancho P, Barneda D, Heeschen C. Hallmarks of cancer stem cell metabolism. Br J Cancer. 2016;114(12):1305\u201312.","journal-title":"Br J Cancer"},{"key":"1619_CR24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drup.2018.03.001","volume":"38","author":"P Icard","year":"2018","unstructured":"Icard P, Shulman S, Farhat D, Steyaert JM, Alifano M, Lincet H. How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist Updat. 2018;38:1\u201311.","journal-title":"Drug Resist Updat"},{"issue":"21","key":"1619_CR25","doi-asserted-by":"crossref","first-page":"11430","DOI":"10.3390\/ijms222111430","volume":"22","author":"M Gavriatopoulou","year":"2021","unstructured":"Gavriatopoulou M, Paschou SA, Ntanasis-Stathopoulos I, Dimopoulos MA. Metabolic disorders in multiple myeloma. Int J Mol Sci. 2021;22(21):11430.","journal-title":"Int J Mol Sci"},{"issue":"2\u20133","key":"1619_CR26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0014-5793(94)00567-2","volume":"347","author":"K Gaston","year":"1994","unstructured":"Gaston K, Fried M. YY1 is involved in the regulation of the bi-directional promoter of the Surf-1 and Surf-2 genes. FEBS Lett. 1994;347(2\u20133):289\u201394.","journal-title":"FEBS Lett"},{"key":"1619_CR27","volume":"8","author":"TCJ Verheul","year":"2020","unstructured":"Verheul TCJ, van Hijfte L, Perenthaler E, Barakat TS. The why of YY1: mechanisms of transcriptional regulation by Yin Yang 1. Front Cell Dev Biol. 2020;8: 592164.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"1619_CR28","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12935-023-03067-6","volume":"23","author":"PH Peng","year":"2023","unstructured":"Peng PH, Chen JL, Wu HH, Yang WH, Lin LJ, Lai JC, Chang JS, Syu JL, Wu HT, Hsu FT, et al. Interplay between lncRNA RP11\u2013367G18.1 variant 2 and YY1 plays a vital role in hypoxia-mediated gene expression and tumourigenesis. Cancer Cell Int. 2023;23(1):266.","journal-title":"Cancer Cell Int"},{"key":"1619_CR29","first-page":"bat007","volume":"2013","author":"AM Guo","year":"2013","unstructured":"Guo AM, Sun K, Su X, Wang H, Sun H. YY1TargetDB: an integral information resource for Yin Yang 1 target loci. Database (Oxford). 2013;2013:bat007.","journal-title":"Database (Oxford)"},{"issue":"17","key":"1619_CR30","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.3390\/cancers15174267","volume":"15","author":"M Jung","year":"2023","unstructured":"Jung M, Bui I, Bonavida B. Role of YY1 in the regulation of anti-apoptotic gene products in drug-resistant cancer cells. Cancers (Basel). 2023;15(17):4267.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1619_CR31","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/10428194.2023.2200516","volume":"64","author":"Q Yin","year":"2023","unstructured":"Yin Q, Shen X, Xu H, Feng W, Shi X, Ju S. YY1-induced LncRNA-TUG1 elevates YOD1 to promote cell proliferation and inhibit bortezomib sensitivity in multiple myeloma. Leuk Lymphoma. 2023;64(6):1161\u201374.","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"1619_CR32","doi-asserted-by":"crossref","first-page":"11305","DOI":"10.1021\/acs.jmedchem.9b02138","volume":"63","author":"Y Liu","year":"2020","unstructured":"Liu Y, He S, Chen Y, Liu Y, Feng F, Liu W, Guo Q, Zhao L, Sun H. Overview of AKR1C3: inhibitor achievements and disease insights. J Med Chem. 2020;63(20):11305\u201329.","journal-title":"J Med Chem"},{"issue":"1","key":"1619_CR33","doi-asserted-by":"crossref","first-page":"e22142","DOI":"10.1002\/ddr.22142","volume":"85","author":"Y Gao","year":"2024","unstructured":"Gao Y, Tao W, Wang S, Duan R, Zhang Z. AKR1C3 silencing inhibits autophagy-dependent glycolysis in thyroid cancer cells by inactivating ERK signaling. Drug Dev Res. 2024;85(1):e22142.","journal-title":"Drug Dev Res"},{"issue":"3","key":"1619_CR34","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.3390\/ijms23031733","volume":"23","author":"NM Nguyen","year":"2022","unstructured":"Nguyen NM, Cho J. Hedgehog pathway inhibitors as targeted cancer therapy and strategies to overcome drug resistance. Int J Mol Sci. 2022;23(3):1733.","journal-title":"Int J Mol Sci"},{"key":"1619_CR35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","volume":"70","author":"P Robak","year":"2018","unstructured":"Robak P, Drozdz I, Szemraj J, Robak T. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018;70:199\u2013208.","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"1619_CR36","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1364","volume":"13","author":"N Osada","year":"2023","unstructured":"Osada N, Kikuchi J, Iha H, Yasui H, Ikeda S, Takahashi N, Furukawa Y. c-FOS is an integral component of the IKZF1 transactivator complex and mediates lenalidomide resistance in multiple myeloma. Clin Transl Med. 2023;13(8): e1364.","journal-title":"Clin Transl Med"},{"issue":"18","key":"1619_CR37","doi-asserted-by":"crossref","first-page":"10396","DOI":"10.1021\/acs.jmedchem.0c00939","volume":"63","author":"S Endo","year":"2020","unstructured":"Endo S, Oguri H, Segawa J, Kawai M, Hu D, Xia S, Okada T, Irie K, Fujii S, Gouda H, et al. Development of novel AKR1C3 inhibitors as new potential treatment for castration-resistant prostate cancer. J Med Chem. 2020;63(18):10396\u2013411.","journal-title":"J Med Chem"},{"issue":"14","key":"1619_CR38","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/pros.24049","volume":"80","author":"JR Hertzog","year":"2020","unstructured":"Hertzog JR, Zhang Z, Bignan G, Connolly PJ, Heindl JE, Janetopoulos CJ, Rupnow BA, McDevitt TM. AKR1C3 mediates pan-AR antagonist resistance in castration-resistant prostate cancer. Prostate. 2020;80(14):1223\u201332.","journal-title":"Prostate"},{"issue":"5","key":"1619_CR39","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1158\/0008-5472.CAN-20-2480","volume":"81","author":"Q Zhou","year":"2021","unstructured":"Zhou Q, Tian W, Jiang Z, Huang T, Ge C, Liu T, Zhao F, Chen T, Cui Y, Li H, et al. A positive feedback loop of AKR1C3-mediated activation of NF-kappaB and STAT3 facilitates proliferation and metastasis in hepatocellular carcinoma. Cancer Res. 2021;81(5):1361\u201374.","journal-title":"Cancer Res"},{"issue":"6","key":"1619_CR40","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/mc.23527","volume":"62","author":"J Chen","year":"2023","unstructured":"Chen J, Zhang J, Tian W, Ge C, Su Y, Li J, Tian H. AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP\/SLC7A11 signaling pathway. Mol Carcinog. 2023;62(6):833\u201344.","journal-title":"Mol Carcinog"},{"key":"1619_CR41","volume":"247","author":"Y Liu","year":"2023","unstructured":"Liu Y, Chen Y, Jiang J, Chu X, Guo Q, Zhao L, Feng F, Liu W, Zhang X, He S, et al. Development of highly potent and specific AKR1C3 inhibitors to restore the chemosensitivity of drug-resistant breast cancer. Eur J Med Chem. 2023;247: 115013.","journal-title":"Eur J Med Chem"},{"issue":"14","key":"1619_CR42","doi-asserted-by":"crossref","first-page":"9537","DOI":"10.1021\/acs.jmedchem.3c00213","volume":"66","author":"S He","year":"2023","unstructured":"He S, Chu X, Wu Y, Jiang J, Fang P, Chen Y, Liu Y, Qiu Z, Xiao Y, Li Z, et al. Development of biaryl-containing aldo-keto reductase 1C3 (AKR1C3) inhibitors for reversing AKR1C3-mediated drug resistance in cancer treatment. J Med Chem. 2023;66(14):9537\u201360.","journal-title":"J Med Chem"},{"issue":"6","key":"1619_CR43","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/cbin.11789","volume":"46","author":"Y Li","year":"2022","unstructured":"Li Y, Tang J, Li J, Du Y, Bai F, Yang L, Li X, Jin X, Wang T. ARID3A promotes the chemosensitivity of colon cancer by inhibiting AKR1C3. Cell Biol Int. 2022;46(6):965\u201375.","journal-title":"Cell Biol Int"},{"issue":"6","key":"1619_CR44","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.7150\/ijbs.70960","volume":"18","author":"M Liu","year":"2022","unstructured":"Liu M, Zhang Y, Wu Y, Jin J, Cao Y, Fang Z, Geng L, Yang L, Yu M, Bu Z, et al. IKZF1 selectively enhances homologous recombination repair by interacting with CtIP and USP7 in multiple myeloma. Int J Biol Sci. 2022;18(6):2515\u201326.","journal-title":"Int J Biol Sci"},{"issue":"5","key":"1619_CR45","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s10565-021-09690-1","volume":"39","author":"F Che","year":"2023","unstructured":"Che F, Ye X, Wang Y, Wang X, Ma S, Tan Y, Mao Y, Luo Z. METTL3 facilitates multiple myeloma tumourigenesis by enhancing YY1 stability and pri-microRNA-27 maturation in m(6)A-dependent manner. Cell Biol Toxicol. 2023;39(5):2033\u201350.","journal-title":"Cell Biol Toxicol"},{"key":"1619_CR46","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.drup.2019.04.001","volume":"43","author":"E Hays","year":"2019","unstructured":"Hays E, Bonavida B. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression. Drug Resist Updat. 2019;43:10\u201328.","journal-title":"Drug Resist Updat"},{"issue":"9","key":"1619_CR47","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.3390\/ijms19092835","volume":"19","author":"E Giroux-Leprieur","year":"2018","unstructured":"Giroux-Leprieur E, Costantini A, Ding VW, He B. Hedgehog signaling in lung cancer: from oncogenesis to cancer treatment resistance. Int J Mol Sci. 2018;19(9):2835.","journal-title":"Int J Mol Sci"},{"key":"1619_CR48","first-page":"153303382311698","volume":"22","author":"L Ma","year":"2023","unstructured":"Ma L, Wang Y, Chen P, Wu S. A review of Hedgehog signaling in radioresistant esophageal cancer: potential treatment target. Technol Cancer Res Treat. 2023;22:15330338231169872.","journal-title":"Technol Cancer Res Treat"},{"key":"1619_CR49","volume":"26","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, Zhang R, Hao C, Pei X, Li J, Wang L. GANT61 and valproic acid synergistically inhibited multiple myeloma cell proliferation via hedgehog signaling pathway. Med Sci Monit. 2020;26: e920541.","journal-title":"Med Sci Monit"},{"key":"1619_CR50","first-page":"1399697","volume":"2022","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Yao G, Yang X, Qiu T, Wang S. Mechanism of targeting the hedgehog signaling pathway against chemotherapeutic resistance in multiple myeloma. J Oncol. 2022;2022:1399697.","journal-title":"J Oncol"},{"key":"1619_CR51","volume":"10","author":"S Wu","year":"2020","unstructured":"Wu S, Kuang H, Ke J, Pi M, Yang DH. Metabolic reprogramming induces immune cell dysfunction in the tumour microenvironment of multiple myeloma. Front Oncol. 2020;10: 591342.","journal-title":"Front Oncol"},{"issue":"3","key":"1619_CR52","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3390\/cancers11030317","volume":"11","author":"T Fan","year":"2019","unstructured":"Fan T, Sun G, Sun X, Zhao L, Zhong R, Peng Y. Tumour energy metabolism and potential of 3-bromopyruvate as an inhibitor of aerobic glycolysis: implications in tumour treatment. Cancers (Basel). 2019;11(3):317.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"1619_CR53","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1158\/1078-0432.CCR-14-1088","volume":"21","author":"S Dalva-Aydemir","year":"2015","unstructured":"Dalva-Aydemir S, Bajpai R, Martinez M, Adekola KU, Kandela I, Wei C, Singhal S, Koblinski JE, Raje NS, Rosen ST, et al. Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin. Clin Cancer Res. 2015;21(5):1161\u201371.","journal-title":"Clin Cancer Res"},{"issue":"6468","key":"1619_CR54","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1126\/science.aav2588","volume":"366","author":"RD Leone","year":"2019","unstructured":"Leone RD, Zhao L, Englert JM, Sun IM, Oh MH, Sun IH, Arwood ML, Bettencourt IA, Patel CH, Wen J, et al. Glutamine blockade induces divergent metabolic programs to overcome tumour immune evasion. Science. 2019;366(6468):1013\u201321.","journal-title":"Science"},{"issue":"7","key":"1619_CR55","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3390\/cancers15071990","volume":"15","author":"I Saltarella","year":"2023","unstructured":"Saltarella I, Altamura C, Campanale C, Laghetti P, Vacca A, Frassanito MA, Desaphy JF. Anti-angiogenic activity of drugs in multiple myeloma. Cancers (Basel). 2023;15(7):1990.","journal-title":"Cancers (Basel)"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01619-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01619-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01619-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:45:05Z","timestamp":1764917105000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01619-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1619"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01619-w","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,29]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"99"}}